Anti platelet agents are important to prevent CVD. Recent study suggests that low on-clopidogrel platelet reactivity linked to reduced CV event risk.

Team@CMHF

A sub-analysis of the GRAVITAS trial suggests that low on-clopidogrel platelet reactivity after percutaneous coronary intervention (PCI) is linked to a reduced cardiovascular (CV) event risk.

The aim of the analysis was to examine the relationship between CV outcomes and on-treatment platelet reactivity (OTR) over the course of the trial.

This observation has important implications for the use of platelet function testing and individualized P2Y12 antagonist therapy in PCI patients.

After a treatment period of 6 months, Price et al observed no significant intergroup difference in the primary endpoint of the combined risk for death from CV causes, nonfatal myocardial infarction (MI), or stent thrombosis, which occurred at a rate of 2.3% in the high- and standard-dose groups, or in the safety endpoint of moderate or severe bleeding (as defined by Global Use of Strategies to Open Occluded Coronary Arteries criteria).

Reference: http://www.incirculation.net/NewsItem/GRAVITAS-Low-onclopidogrel-platelet-reactivity-lin.aspx